SynthesisBMC infectious diseases2016
Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.
Synthesis in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review.Revista da Sociedade Brasileira de Medicina Tropical · 2024Pooled it
- Homelessness and health-related outcomes: an umbrella review of observational studies and randomized controlled trials.BMC medicine · 2022Pooled it
- Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis.The Lancet. Infectious diseases · 2021Pooled it
- The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018Pooled it
- Multimethod analysis of adherence to preventive treatment for tuberculosis: a pragmatic randomized clinical trial.BMC infectious diseases · 2026Trial
- Completion of tuberculosis preventive treatment with 300 mg vs. 100 mg isoniazid tablets: a pragmatic randomized clinical trial.BMC infectious diseases · 2025Trial
- Treatment of latent tuberculosis infection in migrants in primary careThe European respiratory journal · 2024Trial
- Trial
- Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial.JMIR research protocols · 2026Article
- Latent tuberculosis infection screening and treatment outcomes in healthcare workers in Irish hospitals: a multi-centre cohort study.Infection control and hospital epidemiology · 2026Article
- Tuberculosis Disease and Infection in US-Bound International Adoptees: 2016 to 2023.Pediatrics · 2026Article
- A Wolf in Sheep's Clothing: Extensive Musculoskeletal and Cutaneous TB Masquerading as Primary Erythema Nodosum.Case reports in infectious diseases · 2025Article
- Predictors of Tuberculosis Preventive Treatment Completion in College Students: A High Adherence Study in China.Infection and drug resistance · 2025Article
- Tuberculosis in United States-Bound Follow-to-Join Asylees, 2014-2019.The American journal of tropical medicine and hygiene · 2024Article
- Diagnosis and management of tuberculosis infection in inclusion health populations in London.BMC infectious diseases · 2024Article
- Editorial: Addressing tuberculosis infection: an essential step in the fight against tuberculosis.Frontiers in medicine · 2024Article
- Latent Tuberculosis Infection Treatment Practices in Two Large Integrated Health Systems in California, 2009-2018.Open forum infectious diseases · 2023Article
- Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches.Frontiers in medicine · 2023Article
- Community treatment of latent tuberculosis in child and adult refugee populations: outcomes and successes.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundControl of latent tuberculosis infection (LTBI) is an important step towards tuberculosis elimination. Preventive treatment will prevent the development of disease in most cases diagnosed with LTBI. However, low initiation and completion rates affect the effectiveness of preventive treatment. The objective was to systematically review data on initiation rates and completion rates for LTBI treatment regimens in the general population and specific populations with LTBI.
methodsA systematic review of the literature (PubMed, Embase) published up to February 2014 was performed.
resultsForty-five studies on initiation rates and 83 studies on completion rates of LTBI treatment were found. These studies provided initiation rates (IR) and completion rates (CR) in people with LTBI among the general population (IR 26-99 %, CR 39-96 %), case contacts (IR 40-95 %, CR 48-82 %), healthcare workers (IR 47-98 %, CR 17-79 %), the homeless (IR 34-90 %, CR 23-71 %), people who inject drugs (IR 52-91 %, CR 38-89 %), HIV-infected individuals (IR 67-92 %, CR 55-95 %), inmates (IR 7-90 %, CR 4-100 %), immigrants (IR 23-97 %, CR 7-86 %), and patients with comorbidities (IR 82-93 %, CR 75-92 %). Generally, completion rates were higher for short than for long LTBI treatment regimens.
conclusionInitiation and completion rates for LTBI treatment regimens were frequently suboptimal and varied greatly within and across different populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.